Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: Results from the SUNRISE trial

Journal of Rheumatology

Volumn 37, Issue 5, 2010, Pages 917-927

  Mease, Philip J ^a   Cohen, Stanley ^b   Gaylis, Norman B ^f   Chubick, Andrew ^c   Kaell, Alan T ^g   Greenwald, Maria ^d   Agarwal, Sunil ^e   Yin, Ming ^e   Kelman, Ariella ^e  

^a Seattle Rhumatology Associates   (United States)

^b METROPLEX CLINICAL RESEARCH CENTER   (United States)

^c Arthritis Consultation Center   (United States)

^d Desert Medical Advances   (United States)

^e GENENTECH INC   (United States)

^f Arthritis and Rheumatic Disease Specialties   (United States)

^g Rheumatology Associates   (United States)

Author keywords

Methotrexate; Retreatment; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CD19 ANTIGEN; CHIMERIC ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB;

ABDOMINAL ABSCESS; ABSCESS; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; B LYMPHOCYTE; BURSITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HUMAN; HYPOTENSION; IMMUNOGENICITY; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA; OPEN STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PERIRECTAL ABSCESS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RETREATMENT; RHEUMATOID ARTHRITIS; SCORING SYSTEM; THROAT IRRITATION; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; UROSEPSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; METHOTREXATE; MIDDLE AGED; ODDS RATIO; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951777466     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090442     Document Type: Article

References (15)

1. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581 (Pubitemid 38758544)
2. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806 (Pubitemid 44497758)
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
4. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-3908 (Pubitemid 350262316)
5. Emery P, Breedveld F, Martin-Mola E, Pavelka K, Szczepanski L, Hagerty D, et al. Relationship between peripheral B cell levels and loss of EULAR response in rheumatoid arthritis patients treated with rituximab [abstract]. Ann Rheum Dis 2007;66 Suppl II:124. OP0233.
6. Mease PJ, Keystone E, Kaell A, Emery P, St. Clair EW, Dougados M, et al. Predicting outcome of a second course of rituximab for rheumatoid arthritis [abstract]. Ann Rheum Dis 2007;66 Suppl II:434. SAT0019.
7. Mease P, Keystone E, Kaell A, Emery P, St. Clair EW, Dougados M, et al. SDAI and CDAI for predicting outcome of a second course of rituximab for patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2008;67 Suppl II:196. THU0188.
8. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66 Suppl 3:iii56-60.
9. Dougados M, Aletaha D, van Riel P. Disease activity measures for rheumatoid arthritis. Clin Exp Rheumatol 2007;5 Suppl 46:S22-9.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
12. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl JMed 2000;343:1586-1593 (Pubitemid 32162981)
13. Van Gestel A, Anderson J, van Riel P. Modified disease activity scores that include 28 joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1999;38:44-48
14. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008;58:3657-64.
15. Emery P, Mease P, Rubbert-Roth A, Curtis J, Müller-Ladner U, Gaylis N, et al. Retreatment with rituximab based on a treatment to target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis. American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, Philadelphia, PA, October 17-21, 2009: Presentation 2013.